Trillium Therapeutics Inc.
ENHANCEMENT OF CD47 BLOCKADE THERAPY BY PROTEASOME INHIBITORS

Abstract:

CD47- disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include SIRP.alpha.Fc as CD47 blockade drug, and one of bortezomib, ixazomib and carfilzomib as proteasome inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.